Indiqube Spaces Shares Make Weak Debut on Stock Market, List at 9% Discount

Indiqube Spaces Ltd, which launched its Initial Public Offering (IPO) on July 23, 2025 made its debut on Dalal Street today on July 30, 2025. The shares of Indiqube Spaces made a weak debut, listing at discount at both NSE and BSE. 

The shares opened at ₹218.70 on the BSE, marking a discount of 7.7% over the IPO upper price band of ₹237. On NSE, the shares of Indiqube Spaces opened at ₹216, marking a discount of 9%. 

Ahead of its listing, the Grey Market Premium of Indiqube Spaces Ltd stood at ₹0, indicating a flat listing.  After the weak listing, the shares went down further to ₹201.60, down 6.7% from its listing price and 15% below the IPO price. This listing indicates a weaker debut of Indiqube Spaces Shares compared to the grey market estimates.

Indiqube Spaces Overall Subscription Status

On the last day of the bidding window, Indiqube Spaces IPO was subscribed 13.00 times as per the NSE data on July 25, 2025, 5 PM. The public issue saw a subscription of 13.28 times in the retail category, 15.12 times in QIB, and 8.68 times in the NII category.

Indiqube Spaces IPO Details

Indiqube Spaces IPO is a bookbuilding issue of ₹700 crores, consisting of a fresh issue of ₹650 crores and an offer for sale of ₹50 crores. The price band is set between ₹225 and ₹237 per share.

ICICI Securities Limited and JM Financial Limited are the book-running lead managers, while MUFG Intime India Private Limited is the registrar for the Indiqube Spaces IPO.

Indiqube Spaces Business Overview

Founded in 2015 and headquartered in Bengaluru, Indiqube Spaces is a managed workplace solutions company that offers customised workspace solutions to businesses of all sizes, from startups and growing enterprises to large corporates. As of March 31, 2025, the company manages a portfolio of 115 centers across 15 cities, consisting of 105 operational centres and 10 centres. 

Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.

To read the RA disclaimer, please click here